Advocacy intelligence hub — real-time data for patient organizations
Hospital del Rio Hortega — PHASE3
SonoClear AS — NA
City of Hope Medical Center — PHASE1
Marzieh Ebrahimi — PHASE2
Case Comprehensive Cancer Center — PHASE1
St. Joseph's Hospital and Medical Center, Phoenix — EARLY_PHASE1
National University Hospital, Singapore — NA
University of Vermont Medical Center — PHASE2
Sunnybrook Health Sciences Centre — NA
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Gliadel
Guilford Pharmaceuticals, Inc.
Gliadel
(polifeprosan 20 with carmustine)Orphan drugstandardGuilford Pharmaceuticals, Inc.
Alkylating Drug [EPC]
12.1 Mechanism of Action The activity of GLIADEL Wafer is due to release of cytotoxic concentrations of carmustine, a DNA and RNA alkylating agent, in...
Maryam Fouladi, MD, MD
Nationwide Children's Hospital
📍 COLUMBUS, OH
Annick Desjardins, MD, M.D
Duke Health
📍 DURHAM, NC
Jana Portnow, MD
City of Hope Medical Center
📍 DUARTE, CA
Stanislaw R. Burzynski, MD, PhD, M.D., Ph.D
Burzynski Research Institute
📍 HOUSTON, TX
Alissa A Thomas, MD
University of Vermont Medical Center
Jian L. Campian, MD, PhD, MD
Mayo Clinic in Rochester
📍 ROCHESTER, MN